Ondansetron Treatment for Alcoholism
Information source: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Alcoholism
Intervention: ondansetron (Zofran) (Drug)
Phase: Phase 2
Sponsored by: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
The purpose of this study is to: a) evaluate the effectiveness of ondansetron (Zofran) in the
treatment of alcohol dependent patients; b) investigate whether early versus late onset
alcoholism predicts treatment outcome; and c) determine whether the early and late onset
groups respond differently to treatment. Individuals will be "typed" into early onset and
late onset alcoholism groups. Individuals will be randomly assigned to a 12-week outpatient
Official title: Pharmacological Treatment for Alcoholism
Study design: Treatment, Randomized, Double-Blind, Placebo Control, Efficacy Study
Minimum age: 25 Years.
Maximum age: 60 Years.
- Meet criteria for alcohol dependence.
- Subjects with early onset alcoholism must also have a diagnosis of antisocial
- Understand the requirements of the study and be able to complete the questionnaires
and rating scales.
- Current diagnosis of substance dependence or self-report of having used narcotics
(opiates, cocaine, amphetamine-like substances, and hallucinogens) in the 30 day
period prior to study.
- Positive urine drug screen test for narcotics, barbiturates, or benzodiazepines.
- Receiving current psychotropic medications.
- Current history of other psychiatric disorders excluding nicotine dependence.
- Hepatocellular disease.
- Pregnant females.
Locations and Contacts
Substance Abuse Research Center, University of Texas Health Science Center, Houston, Texas 77030, United States
Ending date: April 2000
Last updated: June 23, 2005